Search

Abstrakti Kollektiivinen artikkelimme on sommitelma, jonka tarkoitus on tutkia antroposeeniksi nimetyn hetken kulttuuriperintöä ja antikolonialistisen taidepedagogiikan mahdollisuuksia taidemuseossa. Olemme joukko kuvataidekasvatuksen opiskelijoita, tutkijoita ja taidemuseon pedagogeja. Kerromme toteuttamastamme puolen vuoden mittaisesta opinto- ja tutkimusprojektista, joka rakentui Helsingissä syksyllä 2020 Amos Rex -taidemuseossa avatun Egyptin loisto -näyttelyn ympärille. Antroposeeni, ”ihmisen aika”, on paitsi ympäristökriisi myös ontologinen kriisi, sillä se pakottaa (länsimaisen) ihmisen itseymmärryksen kokonaisvaltaiseen uudelleen arviointiin. Museoilla on perinteisesti nähty olevan tehtävänä ja vastuuna välittää kulttuuriperintöä uusille sukupolville. Kysymme, miten museopedagogiikassa voidaan käsitellä perintöä, jonka alamme yhä paremmin ymmärtää kolonialistisen riiston ja länsimaisen valkoisen ihmisen etuoikeuksien tuotteeksi. Tuo perintö on myös tuottanut tämänhetkiset ympäristö- ja yhteiskunnalliset kriisit. Antroposeenin ja koronapandemian värittämään hetkeen tiivistyy erityistä outoutta, epävarmuutta ja herkkyyttä. Kuvaamme tässä artikkelissa kriittistä prosessia, jonka aikana siirrymme tekstejä korostavasta lähestymistavasta kohti ihmistä laajempaa metodologiaa: aistimaan ja havainnoimaan näyttelyesineiden, näyttelytilan, historioiden ja tulevaisuuksien välille muodostuvia suhteita, tunnelmia ja ilmapiirejä. Tutkimuksellisesti artikkelimme esittelee ajatuksen ilmapiiristä posthumanistisen ja kriittisen museotutkimuksen metodina, jolla voi toisaalta herkistyä antroposeenin tunnetapahtumalle, toisaalta lähestyä ihmistä laajempaa suhteisuutta. Pedagogisella tasolla erittelemme museopedagogisten toteutusten syntyprosesseja, joita leimasi tietoisuus uudenlaisesta vastuusta.

QC 20221031

QC 20220119

QC 20220119

QC 20201215

QC 20201215

QC 20191203

QC 20191202

Affibody-based imaging of HER3 is a promising approach for patient stratification. We investigated the influence of a hydrophilic HEHEHE-tag ((HE)₃-tag) and two different gallium-68/chelator-complexes on the biodistribution of Z08698 with the aim to improve the tracer for PET imaging. Affibody molecules (HE)₃-Z08698-X and Z08698-X (X = NOTA, NODAGA) were produced and labeled with gallium-68. Binding specificity and cellular processing were studied in HER3-expressing human cancer cell lines BxPC-3 and DU145. Biodistribution was studied 3 h p.i. in Balb/c nu/nu mice bearing BxPC-3 xenografts. Mice were imaged 3 h p.i. using microPET/CT. Conjugates were stably labeled with gallium-68 and bound specifically to HER3 in vitro and in vivo. Association to cells was rapid but internalization was slow. Uptake in tissues, including tumors, was lower for (HE)₃-Z08698-X than for non-tagged variants. The neutral [68Ga]Ga-NODAGA complex reduced the hepatic uptake of Z08698 compared to positively charged [68Ga]Ga-NOTA-conjugated variants. The influence of the chelator was more pronounced in variants without (HE)3-tag. In conclusion, hydrophilic (HE)₃-tag and neutral charge of the [68Ga]Ga-NODAGA complex promoted blood clearance and lowered hepatic uptake of Z08698. [68Ga]Ga-(HE)₃-Z08698-NODAGA was considered most promising, providing the lowest blood and hepatic uptake and the best imaging contrast among the tested variants., QC 20190326

QC 20230608

QC 20181217

QC 20230608

Affibody molecules are engineered scaffold proteins, which demonstrated excellent binding to selected tumor-associated molecular abnormalities in vivo and highly sensitive and specific radionuclide imaging of Her2-expressing tumors in clinics. Recently, we have shown that peptide nucleic acid (PNA)-mediated affibody-based pretargeted radionuclide therapy using beta-emitting radionuclide 177Lu extended significantly survival of mice bearing human Her2-expressing tumor xenografts. In this study, we evaluated two approaches to use positron emission tomography (PET) for stratification of patients for affibody-based pretargeting therapy. The primary targeting probe ZHER2:342-SR-HP1 and the secondary probe HP2 (both conjugated with DOTA chelator) were labeled with the positron-emitting radionuclide 68Ga. Biodistribution of both probes was measured in BALB/C nu/nu mice bearing either SKOV-3 xenografts with high Her2 expression or DU-145 xenografts with low Her2 expression. 68Ga-HP2 was evaluated in the pretargeting setting. Tumor uptake of both probes was compared with the uptake of pretargeted 177Lu-HP2. The uptake of both 68Ga-ZHER2:342-SR-HP1 and 68Ga-HP2 depended on Her2-expression level providing clear discrimination of between tumors with high and low Her2 expression. Tumor uptake of 68Ga-HP2 correlated better with the uptake of 177Lu-HP2 than the uptake of 68Ga-ZHER2:342-SR-HP1. The use of 68Ga-HP2 as a theranostics counterpart would be preferable approach for clinical translation., QC 20181127

The human epidermal growth factor receptor 3 (HER3) is involved in the development of cancer resistance towards tyrosine kinase-Targeted therapies. Several HER3-Targeting therapeutics are currently under clinical evaluation. Non-invasive imaging of HER3 expression could improve patient management. Affibody molecules are small engineered scaffold proteins demonstrating superior properties as targeting probes for molecular imaging compared with monoclonal antibodies. Feasibility of in vivo HER3 imaging using affibody molecules has been previously demonstrated. Preclinical studies have shown that the contrast when imaging using anti-HER3 affibody molecules can be improved over time. We aim to develop an agent for PET imaging of HER3 expression using the long-lived positron-emitting radionuclide cobalt-55 (55Co) (T1/2=17.5 h). A long-lived cobalt isotope 57Co was used as a surrogate for 55Co in this study. The anti-HER3 affibody molecule HEHEHE-ZHER3-NOTA was labelled with radiocobalt with high yield, purity and stability. Biodistribution of 57Co-HEHEHE-ZHER3-NOTA was measured in mice bearing DU145 (prostate carcinoma) and LS174T (colorectal carcinoma) xenografts at 3 and 24 h post injection (p.i.). Tumour-To-blood ratios significantly increased between 3 and 24 h p.i. (p<0.05). At 24 h p.i., tumour-To-blood ratios were 6 for DU145 and 8 for LS174T xenografts, respectively. HER3-expressing xenografts were clearly visualized in a preclinical imaging setting already 3 h p.i., and contrast further improved at 24 h p.i. In conclusion, the radiocobalt-labelled anti-HER3 affibody molecule, HEHEHE-ZHER3-NOTA, is a promising tracer for imaging of HER3 expression in tumours., QC 20171127

QC 20200311

QC 20200310